BRAIN CANCER

Daniela A. Bota, MD, medical director of Neuro-Oncology at University of California Irvine, discusses the findings from a dose-escalation trial of marizomib.

The anticancer immunotherapy vaccine SL-701, when used with immunostimulants, induced antitumor activity in patients with relapsed/refractory glioblastoma both alone and in combination with bevacizumab, according to updated phase II results from the 2-stage STML-701-0114 trial presented at the 2018 ASCO Annual Meeting.

According to phase I findings recently published in the<em> New England Journal of Medicine,&nbsp;</em>^&nbsp;the&nbsp;recombinant oncolytic poliovirus PVSRIPO demonstrated&nbsp;a 2- and 3-year overall survival (OS) rate of 21% (95% CI, 11%-33%) for patients with recurrent grade IV malignant glioblastoma.

The Hassenfeld Children&rsquo;s Hospital at NYU Langone and Perlmutter Cancer Center recently welcomed 2 new leaders in pediatric oncology, Elizabeth A. Raetz, MD, and Theodore P. Nicolaides, MD.

In a recent phase Ib study, the combination of carboxyamidotriazole orotate (CTO) and&nbsp;temozolomide (Temodar)&nbsp;produced positive safety and efficacy results in patients with glioblastoma (GBM) or anaplastic gliomas, with or without treatment with radiotherapy.

The use of personalized neoantigen vaccines demonstrated promising results in a recent phase I/Ib trial of patients with glioblastoma.

Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields, an antimitotic treatment.